Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-100 in Dry Eye Disease
NCT05241470Phase 2Completed
- Sponsor
- Stuart Therapeutics
- Start
- May 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vezocolmitide in dry eye disease (DED) (3 arms), sponsored by Stuart Therapeutics. Primary endpoints: Change From Baseline of Total Corneal Fluorescein Staining (Ora Calibra® Scale) in the Study Eye at Day 29 and Change From Baseline of Ocular Discomfort in the Study Eye at Day 29. Started May 2021; status: completed.
02
Drugs
vezocolmitide
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05241470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241470.